United States Food and Drug Administration (''USFDA'') conducted a cGMP inspection at our API manufacturing facility in Bommasandra, Bangalore from 20th January, 2020 to 24th January, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity. The Company is committed to address these observations and will submit its response to the USFDA within the stipulated time.